Douglas Falk is the co-founder of Vita Therapeutics. He joined Vita as Chief Executive Officer in 2019, with 6 years of experience in the investment world with a particular focus in biotechnology at Brown Advisory. He was also involved in the formation of OptoStem. In addition, Falk currently sits on the Board of Directors for the Johns Hopkins Biotechnology Investment Group.

Falk received his M.S. from Johns Hopkins University in biotechnology and his BA from Goucher College in Economics and Business Management.